Sirio Pharma (300791) — Cash Flow Quality Index
Sirio Pharma (300791) has a Cash Flow Quality Index of 1.42x as of June 2023. Operating cash flow of CN¥101.61 Million exceeds net income of CN¥71.79 Million, indicating high earnings quality where cash backs reported profits. Also explore 300791 asset base for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Sirio Pharma Cash Flow Quality Index (2016–2024)
Historical Cash Flow Quality Index for Sirio Pharma across 9 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Sirio Pharma tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Sirio Pharma (2016–2024)
Year-by-year earnings quality comparison for Sirio Pharma. For live market cap and the full company financial profile, see Sirio Pharma (300791) total market value.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.74x | CN¥566.97 Million | CN¥325.06 Million | ▲ +27.0% |
| 2023 | 1.37x | CN¥386.08 Million | CN¥281.04 Million | ▼ -34.4% |
| 2022 | 2.10x | CN¥444.86 Million | CN¥212.29 Million | ▲ +42.3% |
| 2021 | 1.47x | CN¥341.38 Million | CN¥231.83 Million | ▲ +18.6% |
| 2020 | 1.24x | CN¥319.57 Million | CN¥257.37 Million | ▼ -23.6% |
| 2019 | 1.63x | CN¥231.60 Million | CN¥142.53 Million | ▲ +80.0% |
| 2018 | 0.90x | CN¥183.46 Million | CN¥203.23 Million | ▲ +90.8% |
| 2017 | 0.47x | CN¥49.35 Million | CN¥104.30 Million | ▲ +438.9% |
| 2016 | -0.14x | CN¥-98.26 Million | CN¥703.73 Million | — |